Headlands Technologies’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
Other funds holding ENTA
KAM
SSC
Headlands Technologies's ENTA Position: Q2 2026 in Review
Headlands Technologies reduced its Enanta Pharmaceuticals (ENTA) stake by 22% in Q2 2026, selling an estimated $66.3K and leaving 17,686 shares worth $258K. The position accounts for 0.03% of the portfolio, ranked #560.
Headlands Technologies first reported a position in ENTA in Q1 2024 and has held it in 6 quarters since. The position peaked at $356K in Q4 2025. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Headlands Technologies held 17,686 shares of Enanta Pharmaceuticals worth $258K as of Q2 2026.
- Headlands Technologies sold 4,932 Enanta Pharmaceuticals shares in Q2 2026, an estimated $66.3K.
- Enanta Pharmaceuticals made up 0.03% of Headlands Technologies's portfolio in Q2 2026, its #560 holding.
- Headlands Technologies first reported a position in Enanta Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
- Headlands Technologies's Enanta Pharmaceuticals position peaked at $356K in Q4 2025.
- 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.